BioNTech SE, a biotechnology company, develops and commercializes immunotherapies to treat cancer and infectious diseases in Germany. The company develops BNT111, which is in Phase 2 clinical trial for advance melanoma; BNT113, which is in Phase 2 clinical trial to treat head and neck squamous cell carcinoma; BNT116, which is in Phase I clinical trial for non-small cell lung cancer; BNT142, which is in phase 1/2 clinical trial for multiple solid tumors; BNT151, which is in phase 1/2 clinical trial for solid tumors; BNT152+BNT153, which is in phase 1 clinical trial for solid tumors; and BNT122/RO7198457, which is in Phase 2 clinical trial to treat adjuvant high-risk muscle-invasive urothelial carcinoma, colorectal cancer, pancreatic ductal adenocarcinoma, advance melanoma, as well as in phase 1a/1b clinical trial for advanced/metastatic solid tumors. It also develops BNT211, which is in phase 1 clinical trial to treat CLDN6+ solid tumors; BNT221, phase 1 clinical trial for the treatment of cancer; BNT311/GEN1046 (acasunlimab), which is in phase 3 clinical trial for solid tumors; BNT312/GEN1042, which is in phase 1/2 and 1 clinical trial to treat solid tumors; BNT314/GEN1059, which is in Phase 1/2 clinical trial for advanced or metastatic solid tumors; BNT315/GEN1055, which is in phase 1/2 clinical trial for advanced solid tumors; BNT317, which is in phase 1 clinical trial for advanced solid tumors; BNT327, which is in phase 1/2, 2, and 3 clinical trial to treat small cell lung cancer, advanced/metastatic tnbc, neuroendocrine neoplasm, malignant mesothelioma, EGFR-mutant non-squamous, hepatocellular carcinoma, and advanced solid tumors; and BNT316/ONC-392, which is in phase 1/2, 2, and 3 clinical trial to treat metastatic, non-small cell lung cancer, platinum-resistant ovarian cancer, metastatic castration resistant prostate cancer, and advanced or metastatic solid tumor. BioNTech SE was incorporated in 2008 and is headquartered in Mainz, Germany.

BioNTech SE

In a report released yesterday, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE, with a price target of $155.00. The compan...

BioNTech SE (BNTX) Gets a Buy from Berenberg Bank

In a report released yesterday, Geoff Meacham from Citi maintained a Buy rating on BioNTech SE, with a price target of $145.00. The company’s share...

Citi Sticks to Their Buy Rating for BioNTech SE (BNTX)

BioNTech SE ( ($BNTX) ) has issued an announcement. On December 9, 2025, BioNTech SE and Bristol Myers Squibb announced interim results from a glob...

BioNTech and BMS Report Promising Phase 2 Results for TNBC Treatment

BioNTech SE ( ($BNTX) ) has provided an update. On December 6, 2025, BioNTech SE and OncoC4, Inc. presented promising data from the non-pivotal dos...

BioNTech and OncoC4 Report Positive Phase 3 Trial Results for Gotistobart in Lung Cancer

BioNTech SE ( ($BNTX) ) has issued an update. On December 3, 2025, BioNTech SE announced that it has satisfied the minimum condition of its exchang...

BioNTech Satisfies Minimum Condition in CureVac Exchange Offer

Jefferies analyst Akash Tewari maintained a Buy rating on BioNTech SE today and set a price target of $151.00. Tewari covers the Healthcare sector,...

Jefferies Sticks to Their Buy Rating for BioNTech SE (BNTX)

Shares of major COVID-19 vaccine makers, Moderna ($MRNA), BioNTech ($BNTX), and Novavax ($NVAX) fell 6%, 5%, and 4%, respectively, on Monday. The d...

MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today

BioNTech SE ( ($BNTX) ) has provided an announcement. On November 26, 2025, BioNTech SE announced the approval of its exchange offer for all outsta...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	BNTX	$94.81	-1.24%	849.05K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	BNTX	$94.81	-1.2%	849.05K
3
4
5
6

BNTX

BNTX

Get BioNTech SE Data in Excel

Get BioNTech SE Data in Excel